Bora Biologics has been recognized as the 2025 Top Microbial Development and Manufacturer by Pharma Tech Outlook, highlighting the company’s leadership in delivering high‑quality, scalable biologics solutions for global biopharmaceutical partners.

The recognition follows a recent interview with Stephen Lam, CEO of Bora Biologics, in which he shared insights into the company’s role as a premier Contract Development and Manufacturing Organization (CDMO). With dual operational hubs in San Diego, California, and Zhubei, Taiwan, Bora Biologics supports programs from early‑stage development through commercial manufacturing.

Advancing Microbial Biologics from Development to Commercialization
In the interview, Stephen Lam discussed the technical and operational challenges inherent in scaling microbial biologics while maintaining regulatory rigor and accelerating time to market. He emphasized Bora Biologics’ ability to balance speed, compliance, and product quality, supported by deep process expertise and integrated development‑to‑manufacturing capabilities.

Bora Biologics combines strengths in microbial and mammalian platforms, offering innovative, end‑to‑end solutions that enhance efficiency, consistency, and product quality across the development lifecycle. This integrated approach enables clients to advance complex biologics programs with confidence and clarity.

This recognition from Pharma Tech Outlook underscores Bora Biologics’ commitment to scientific excellence, operational discipline, and client partnership, as the company continues to help biotech and pharmaceutical innovators bring transformative therapies to patients worldwide.

About Bora Biologics
Bora Biologics is a global CDMO offering agile, comprehensive end-to-end solutions for biopharma companies worldwide. With a proven track record of over 100 successful cGMP manufacturing batches, Bora Biologics leverages its state-of-the-art, FDA-registered facility in the U.S. and deep expertise in biologics development and manufacturing—including its own FDA-licensed and Health Canada approved product—to enhance time and cost efficiencies while ensuring effective pathways to market for its clients. Bora Biologics combines innovative early-phase development and late-stage manufacturing capabilities with the expertise and reputation of Bora Pharmaceuticals for flexible and scalable fill/finish services, including stability testing and final packaging of clinical and commercial products.